» Articles » PMID: 39236027

Identifying Crucial LncRNAs and MRNAs in Hypoxia-induced A549 Lung Cancer Cells and Investigating Their Underlying Mechanisms Via High-throughput Sequencing

Overview
Journal PLoS One
Date 2024 Sep 5
PMID 39236027
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Rapid proliferation and outgrowth of tumor cells frequently result in localized hypoxia, which has been implicated in the progression of lung cancer. The present study aimed to identify key long non-coding RNAs (lncRNAs) and messenger RNAs (mRNAs) involved in hypoxia-induced A549 lung cancer cells, and to investigate their potential underlying mechanisms of action.

Methods: High-throughput sequencing was utilized to obtain the expression profiles of lncRNA and mRNA in both hypoxia-induced and normoxia A549 lung cancer cells. Subsequently, a bioinformatics analysis was conducted on the differentially expressed molecules, encompassing functional enrichment analysis, protein-protein interaction (PPI) network analysis, and competitive endogenous RNA (ceRNA) analysis. Finally, the alterations in the expression of key lncRNAs and mRNAs were validated using real-time quantitative PCR (qPCR).

Results: In the study, 1155 mRNAs and 215 lncRNAs were identified as differentially expressed between the hypoxia group and the normoxia group. Functional enrichment analysis revealed that the differentially expressed mRNAs were significantly enriched in various pathways, including the p53 signaling pathway, DNA replication, and the cell cycle. Additionally, key lncRNA-miRNA-mRNA relationships, such as RP11-58O9.2-hsa-miR-6749-3p-XRCC2 and SNAP25-AS1-hsa-miR-6749-3p-TENM4, were identified. Notably, the qPCR assay demonstrated that the expression of SNAP25-AS1, RP11-58O9.2, TENM4, and XRCC2 was downregulated in the hypoxia group compared to the normoxia group. Conversely, the expression of LINC01164, VLDLR-AS1, RP11-14I17.2, and CDKN1A was upregulated.

Conclusion: Our findings suggest a potential involvement of SNAP25-AS1, RP11-58O9.2, TENM4, XRCC2, LINC01164, VLDLR-AS1, RP11-14I17.2, and CDKN1A in the development of hypoxia-induced lung cancer. These key lncRNAs and mRNAs exert their functions through diverse mechanisms, including the competitive endogenous RNA (ceRNA) pathway.

References
1.
Tang Y, Li M, Wang J, Pan Y, Wu F . CytoNCA: a cytoscape plugin for centrality analysis and evaluation of protein interaction networks. Biosystems. 2014; 127:67-72. DOI: 10.1016/j.biosystems.2014.11.005. View

2.
Zamagni A, Pasini A, Pirini F, Ravaioli S, Giordano E, Tesei A . CDKN1A upregulation and cisplatin‑pemetrexed resistance in non‑small cell lung cancer cells. Int J Oncol. 2020; 56(6):1574-1584. PMC: 7170038. DOI: 10.3892/ijo.2020.5024. View

3.
Schoenfeld A, Arbour K, Rizvi H, Iqbal A, Gadgeel S, Girshman J . Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. Ann Oncol. 2019; 30(5):839-844. PMC: 7360149. DOI: 10.1093/annonc/mdz077. View

4.
Goto Y, Zeng L, Yeom C, Zhu Y, Morinibu A, Shinomiya K . UCHL1 provides diagnostic and antimetastatic strategies due to its deubiquitinating effect on HIF-1α. Nat Commun. 2015; 6:6153. PMC: 4317501. DOI: 10.1038/ncomms7153. View

5.
Dong H, Wang R, Jin X, Zeng J, Pan J . LncRNA DGCR5 promotes lung adenocarcinoma (LUAD) progression via inhibiting hsa-mir-22-3p. J Cell Physiol. 2017; 233(5):4126-4136. DOI: 10.1002/jcp.26215. View